Table 6.
Patterns of antihypertensive drug group prescribing for patients with primary outcome data
| Drug category | No (%) of patients prescribed drug category | No (%) of patients with change in DDD from baseline to follow-up | |||||
|---|---|---|---|---|---|---|---|
| Baseline | Follow-up | Decreased | Same | Increased | |||
| Thiazides: | |||||||
| Usual care | 75 (42) | 78 (44) | 4 (2) | 166 (94) | 7 (4) | ||
| Monitored | 71 (39) | 85 (47) | 4 (2) | 160 (88) | 18 (10) | ||
| β blockers: | |||||||
| Usual care | 29 (16) | 31 (18) | 2 (1) | 171 (97) | 4 (2) | ||
| Monitored | 32 (18) | 34 (19) | 2 (1) | 177 (97) | 3 (2) | ||
| ACE inhibitors: | |||||||
| Usual care | 71 (40) | 67 (38) | 5 (3) | 171 (97) | 7 (4) | ||
| Monitored | 81 (45) | 98 (54) | 4 (2) | 156 (86) | 12 (7) | ||
| Angiotensin receptor blockers: | |||||||
| Usual care | 31 (18) | 37 (21) | 1 (1) | 169 (95) | 7 (4) | ||
| Monitored | 25 (14) | 36 (20) | 1 (1) | 169 (93) | 12 (7) | ||
| Calcium channel blockers: | |||||||
| Usual care | 58 (33) | 64 (36) | 2 (1) | 167 (94) | 8 (5) | ||
| Monitored | 52 (29) | 80 (44) | 2 (1) | 148 (81) | 32 (18) | ||
| Diuretics: | |||||||
| Usual care | 3 (2) | 2 (1) | 1 (1) | 176 (99) | 0 (0) | ||
| Monitored | 7 (4) | 10 (5) | 0 (0) | 178 (98) | 4 (2) | ||
| α blockers: | |||||||
| Usual care | 16 (9) | 18 (10) | 1 (1) | 173 (98) | 3 (2) | ||
| Monitored | 7 (4) | 13 (7) | 1 (1) | 175 (96) | 6 (3) | ||
| Others: | |||||||
| Usual care | 4 (2) | 4 (2) | 0 (0) | 177 (100) | 0 (0) | ||
| Monitored | 4 (2) | 5 (3) | 1 (1) | 178 (98) | 3 (2) | ||
DDD=defined daily dose; ACE=angiotensin converting enzyme.
Data were missing for 24 of 201 (12%) in usual care group and 18 of 200 (9%) in monitored group.